

# Carla Verri

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/3072715/carla-verri-publications-by-citations.pdf>

**Version:** 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

22

papers

1,529

citations

16

h-index

28

g-index

28

ext. papers

1,700

ext. citations

6.4

avg, IF

3.83

L-index

#	Paper	IF	Citations
22	MicroRNA signatures in tissues and plasma predict development and prognosis of computed tomography detected lung cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2011</b> , 108, 3713-8	11.5	571
21	Clinical utility of a plasma-based miRNA signature classifier within computed tomography lung cancer screening: a correlative MILD trial study. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 768-73	2.2	290
20	Plasma DNA quantification in lung cancer computed tomography screening: five-year results of a prospective study. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2009</b> , 179, 69-74	10.2	82
19	Mir-660 is downregulated in lung cancer patients and its replacement inhibits lung tumorigenesis by targeting MDM2-p53 interaction. <i>Cell Death and Disease</i> , <b>2014</b> , 5, e1564	9.8	64
18	Circulating microRNA signature as liquid-biopsy to monitor lung cancer in low-dose computed tomography screening. <i>Oncotarget</i> , <b>2015</b> , 6, 32868-77	3.3	57
17	Fragile histidine triad gene inactivation in lung cancer: the European Early Lung Cancer project. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2009</b> , 179, 396-401	10.2	55
16	YAP1 acts as oncogenic target of 11q22 amplification in multiple cancer subtypes. <i>Oncotarget</i> , <b>2014</b> , 5, 2608-21	3.3	52
15	Assessment of circulating microRNAs in plasma of lung cancer patients. <i>Molecules</i> , <b>2014</b> , 19, 3038-54	4.8	50
14	Circulating miRNAs and PD-L1 Tumor Expression Are Associated with Survival in Advanced NSCLC Patients Treated with Immunotherapy: a Prospective Study. <i>Clinical Cancer Research</i> , <b>2019</b> , 25, 2166-2173	12.9	47
13	Novel method to detect microRNAs using chip-based QuantStudio 3D digital PCR. <i>BMC Genomics</i> , <b>2015</b> , 16, 849	4.5	46
12	Circulating mir-320a promotes immunosuppressive macrophages M2 phenotype associated with lung cancer risk. <i>International Journal of Cancer</i> , <b>2019</b> , 144, 2746-2761	7.5	37
11	Therapeutic use of microRNAs in lung cancer. <i>BioMed Research International</i> , <b>2014</b> , 2014, 756975	3	34
10	Complement C4d-specific antibodies for the diagnosis of lung cancer. <i>Oncotarget</i> , <b>2018</b> , 9, 6346-6355	3.3	28
9	Recent advances of microRNA-based molecular diagnostics to reduce false-positive lung cancer imaging. <i>Expert Review of Molecular Diagnostics</i> , <b>2015</b> , 15, 801-13	3.8	27
8	MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier (MSC) for Lung Cancer Screening. <i>Journal of Visualized Experiments</i> , <b>2017</b> ,	1.6	21
7	Elevated levels of the acute-phase serum amyloid are associated with heightened lung cancer risk. <i>Cancer</i> , <b>2010</b> , 116, 1326-35	6.4	21
6	EUELC project: a multi-centre, multipurpose study to investigate early stage NSCLC, and to establish a biobank for ongoing collaboration. <i>European Respiratory Journal</i> , <b>2009</b> , 34, 1477-86	13.6	14

5	Oral maintenance metronomic vinorelbine versus best supportive care in advanced non-small-cell lung cancer after platinum-based chemotherapy: The MA.NI.LA. multicenter, randomized, controlled, phase II trial. <i>Lung Cancer</i> , <b>2019</b> , 132, 17-23	5.9	11
4	Mutational Profile from Targeted NGS Predicts Survival in LDCT Screening-Detected Lung Cancers. <i>Journal of Thoracic Oncology</i> , <b>2017</b> , 12, 922-931	8.9	10
3	Plasma DNA levels in spiral CT-detected and clinically detected lung cancer patients: a validation analysis. <i>Lung Cancer</i> , <b>2009</b> , 66, 270-1	5.9	6
2	MicroRNA Profile of Lung Tumor Tissues Is Associated with a High Risk Plasma miRNA Signature. <i>Microarrays (Basel, Switzerland)</i> , <b>2016</b> , 5,		5
1	Abstract A19: Origin and functional role of plasma circulating miRNAs.. <i>Clinical Cancer Research</i> , <b>2014</b> , 20, A19-A19	12.9	1